Tracers / [131I]I-BNF03
[131I]I-BNF03
Also written as [I-131]I-BNF03
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- dual-modality radio-fluorescent probe (benzothiazole-based, FITC-conjugated iodinated compound)
- Target / mechanism
- Binding to estrogen receptor alpha (ERα) PMID 42519085
- Clinical application
- Image-guided surgery / imaging of breast cancer cells (MCF-7, MDA-MB-231) PMID 42519085
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | 97.04 ± 1.61% | BNF03 | 42519085 2026 RSC Adv The fluorescent probes BNF03 and WS03 were labeled with a β-/γ radionuclide (iodine-131) via direct radioiodination at low pH (pH = 4, using glacial acetic acid). |
Need this precursor?We can point you to suppliers for [131I]I-BNF03, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42519085. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.